Patents Assigned to ARO BIOTHERAPEUTICS COMPANY
  • CD71 binding fibronectin type III domains
    Patent number: 12037379
    Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
    Type: Grant
    Filed: April 14, 2022
    Date of Patent: July 16, 2024
    Assignee: ARO Biotherapeutics Company
    Inventors: Russell C. Addis, Zhanna Druzina, Robert V. Kolakowski, Steven G. Nadler, Karyn T. O'Neil, Yao Xin
  • FN3 domain-siRNA conjugates and uses thereof
    Patent number: 11781138
    Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: October 10, 2023
    Assignee: Aro Biotherapeutics Company
    Inventors: Russell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin
  • CD71 binding fibronectin type III domains
    Patent number: 11628222
    Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: April 18, 2023
    Assignee: ARO BIOTHERAPEUTICS COMPANY
    Inventors: Russell C. Addis, Zhanna Druzina, Robert Kolakowski, Swapnil Kulkarni, Steven G. Nadler, Karyn O'Neil, Yao Xin